In-Depth Insights into the Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market: Growth, Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market grown in recent years?
Over the past few years, the market size for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing has seen substantial growth. Expected to expand from $1.98 billion in 2024 to $2.2 billion in 2025, this market is projected to have a compound annual growth rate (CAGR) of 11.1%. Factors like the rise of antibiotic resistance, increased awareness drives and education, along with policy shifts are credited for the past period’s growth.
How is the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market size expected to evolve during the forecast period?
Expectations are high for a significant increase in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market over the coming years. The projection is for a growth to $3.33 billion by 2029, with a compound annual growth rate (CAGR) of 10.9%. This surge during the forecasted period can be credited to the rise of telehealth and telemedicine, emphasis on personalized medicine, expansion of point-of-care testing, and strategies focused on population health management. Key trends foreseen in this period incorporate the proliferation of rapid point-of-care testing, individualized testing methodologies, multi-disease testing platforms, and the development of community-oriented testing and outreach initiatives.
Get your chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report here!
Which key drivers are propelling the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market’s growth?
The rise in sexually transmitted infections (STIs) is projected to bolster the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market. STIs, which are diseases transmitted via sexual contact, arise from infections with bacteria, viruses, or parasites. The climbing rates of these infections can be attributed to the lack of comprehensive sex education, escalated sexual activity, stigma, and obstacles. The purpose of chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing is to identify and manage STIs by facilitating early diagnosis, treatment, and prevention of further transmission. As an illustration, data from the World Health Organization, Switzerland, showed that every day, over one million STIs are contracted globally and each year, around 374 million new infections are estimated to surface with one of the four curable STIs. Therefore, the escalating numbers of STIs are fueling the advancement of the CTNG testing market.
What are the market segments in the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing industry?
The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Subsegments:
1) By Laboratory: Nucleic Acid Amplification Tests (NAAT), Polymerase Chain Reaction (PCR) Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Culture Tests, Direct Fluorescent Antibody (DFA) Tests
2) By Point Of Care Testing: Rapid Diagnostic Tests (RDT), Lateral Flow Assays, Immunochromatographic Tests, Self-Testing Kits, Loop-Mediated Isothermal Amplification (LAMP), Microfluidics-Based Tests
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14667&type=smp
Which leading companies are shaping the growth of the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market?
Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech
What key trends are currently impacting the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market’s development?
In the Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) testing market, leading companies are concentrating on developing cutting-edge testing solutions, such as the BD COR MX/PX System, to fulfill the demand for effective, precise, and large-scale testing processes aimed at combating the growing prevalence of sexually transmitted infections. The BD COR MX/PX System, a state-of-the-art laboratory tool, is able to quickly and effectively scrutinize numerous samples to detect infectious pathogens. In May 2022, for example, the US-based medical device firm, Becton Dickinson and Company, introduced its novel, fully-automated, high-throughput molecular diagnostic platform for infectious diseases, named the BD COR MX/PX System. This platform is tailored to optimize the workflow in sizable labs that manage a vast range of infectious disease tests, such as CT and NG testing. It employs robotics and software algorithms to automate the whole procedure, from the reception of samples to the delivery of results, potentially minimizing delays for test outcomes and greatly enhancing efficiency. Features of the system include automation, high-throughput capacity, dual DNA targeting, and a modular and scalable design.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14667
Which geographic areas are influencing the growth of the chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Chronic Disease Management Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report
Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024
Chronic Kidney Disease Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
